For the quarter ending 2025-09-30, LXRX made $14,182,000 in revenue. -$12,726,000 in net income. Net profit margin of -89.73%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 14,182,000 | 28,866,000 | 1,262,000 | 13,842,000 |
| Cost of sales | 10,000 | 33,000 | 30,000 | 189,500 |
| Research and development | 18,757,000 | 15,747,000 | 15,303,000 | 20,528,500 |
| Selling, general and administrative, including stock-based compensation of 1,612, 1,341, 4,656 and 7,229 respectively | 7,602,000 | 9,350,000 | 11,608,000 | 32,159,000 |
| Total operating expenses | 26,369,000 | 25,130,000 | 26,941,000 | 52,877,000 |
| Loss from operations | -12,187,000 | 3,736,000 | -25,679,000 | -39,035,000 |
| Interest and other expense | 2,155,000 | 2,318,000 | 1,835,000 | 4,403,000 |
| Interest income and other | 1,573,000 | 1,834,000 | 2,219,000 | 2,356,500 |
| Net loss | -12,769,000 | 3,252,000 | -25,295,000 | -41,081,500 |
| Unrealized gain (loss) on investments | 43,000 | -39,000 | -94,000 | -155,500 |
| Comprehensive loss | -12,726,000 | 3,213,000 | -25,389,000 | -41,237,000 |
| Net loss per common share, basic (usd per share) | -0.04 | 0.01 | -0.07 | -0.14 |
| Net loss per common share, diluted (usd per share) | -0.04 | 0.01 | -0.07 | -0.14 |
| Weighted average common shares outstanding, basic (in shares) | 363,399,000 | 363,294,000 | 362,073,000 | -176,148,500 |
| Weighted average common shares outstanding, diluted (in shares) | 363,399,000 | 363,570,000 | 362,073,000 | -176,148,500 |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)